Fosun Pharma (02196.HK): FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria have initiated a Phase III clinical trial in China.

Zhitong Finance APP news, Fosun Pharma (02196.HK) announced that recently, Shanghai Fosun Pharmaceutical Development Co., Ltd., a controlled subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company"), initiated a Phase III clinical trial in China for FXS6837 capsules (original project code: XH-S003, hereinafter referred to as "FXS6837") for the treatment of paroxysmal nocturnal hemoglobinuria.